Review
Open access
Aug 2026
The ERK MAPK pathway in mesenchymal glioblastoma: tumorigenesis, microenvironmental reprogramming, and the therapeutic promise of RAS(ON) multi-selective inhibition
The potential effect of daraxonrasib as an emerging targeted therapeutic candidate in MES-GBM is discussed, highlighting the need of further research and clinical evaluation to better determine its therapeutic efficacy dedicated GBM preclinical models.
Uma M. Basole, Mary M. Fitzpatric, Joseph I. Donohoe et al.
· Frontiers in Molecular Neuro... · 0 citations